MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/jco.23.00307

Медицинская библиотека · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023

Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group.

Kamat Ashish M, Apolo Andrea B, Babjuk Marek, Bivalacqua Trinity J, Black Peter C, Buckley Roger, Campbell Matthew T, Compérat Eva, Efstathiou Jason A, Grivas Petros, Gupta Shilpa, Kurtz Neil J, Lamm Donald, Lerner Seth P, Li Roger, McConkey David J, Palou Redorta Joan, Powles Thomas, Psutka Sarah P, Shore Neal, Steinberg Gary D, Sylvester Richard, Witjes J Alfred, Galsky Matthew D

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

PURPOSE: There is a significant unmet need for new and efficacious therapies in urothelial cancer (UC). To provide recommendations on appropriate clinical trial designs across disease settings in UC, the Society for Immunotherapy of Cancer (SITC) and the International Bladder Cancer Group (IBCG) convened a multidisciplinary, international consensus panel.

METHODS

Through open communication and scientific debate in small- and whole-group settings, surveying, and responses to clinical questionnaires, the consensus panel developed recommendations on optimal definitions of the disease state, end points, trial design, evaluations, sample size calculations, and pathology considerations for definitive studies in low- and intermediate-risk nonmuscle-invasive bladder cancer (NMIBC), high-risk NMIBC, muscle-invasive bladder cancer in the neoadjuvant and adjuvant settings, and metastatic UC. The expert panel also solicited input on the recommendations through presentations and public discussion during an open session at the 2021 Bladder Cancer Advocacy Network (BCAN) Think Tank (held virtually).

RESULTS

The consensus panel developed a set of stage-specific bladder cancer clinical trial design recommendations, which are summarized in the table that accompanies this text.

CONCLUSION

These recommendations developed by the SITC-IBCG Bladder Cancer Clinical Trial Design consensus panel will encourage uniformity among studies and facilitate drug development in this disease.

Для цитирования: Kamat Ashish M, Apolo Andrea B, Babjuk Marek, Bivalacqua Trinity J, Black Peter C, Buckley Roger, Campbell Matthew T, Compérat Eva, Efstathiou Jason A, Grivas Petros, Gupta Shilpa, Kurtz Neil J, Lamm Donald, Lerner Seth P, Li Roger, McConkey David J, Palou Redorta Joan, Powles Thomas, Psutka Sarah P, Shore Neal, Steinberg Gary D, Sylvester Richard, Witjes J Alfred, Galsky Matthew D. Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023. DOI: 10.1200/jco.23.00307.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.